Forest Laboratories metabolic, neurology news
Forest's Forest Pharmaceutical Inc. subsidiary agreed to pay more than $313 million to settle criminal and civil charges that it sold an unapproved hypothyroidism drug, improperly promoted antidepressants and obstructed an FDA investigation.
Forest will plead guilty to distributing an unapproved drug, Levothroid levothyroxine, from 2001-03 after FDA established that products containing levothyroxine sodium required NDA registration. The company also will plead guilty to distribution of a misbranded drug for its off-label promotion of depression drug Celexa citalopram in pediatric populations from 1998-2002. Additionally, Forest will plead guilty to a charge of obstructing an agency proceeding, relating to false statements made by employees during a 2003 FDA inspection. ...